Romiplostim Prevents Chemotherapy-Induced Thrombocytopenia in Phase 3 Trial
核心洞察
Romiplostim demonstrated significant efficacy in preventing chemotherapy-induced thrombocytopenia in a phase 3 trial, allowing 84% of patients to maintain full-dose chemotherapy compared to 36% in the placebo group.
The RECITE trial included 165 patients with advanced colorectal, gastroesophageal, or pancreatic cancer, showing romiplostim reduced the odds of chemotherapy dose reduction by more than 10-fold.
This breakthrough addresses an unmet medical need as no approved medications currently exist for chemotherapy-induced thrombocytopenia, which forces oncologists to reduce or delay cancer treatment.
Results from a global phase 3 clinical trial led by investigators at Mass General Brigham (搜索) demonstrate that romiplostim can effectively prevent chemotherapy-induced thrombocytopenia, a common complication that forces oncologists to reduce or delay cancer treatment. The findings, published in the New England Journal of Medicine, represent a significant breakthrough for patients whose cancer care is compromised by this challenging side effect.
"This work has been nearly a decade in the making, and it is so important because there are no available approved medications for chemotherapy-induced thrombocytopenia, which drastically increases a patient's risk of major or life-threatening bleeding," said lead author Hanny Al-Samkari, MD, a classical hematologist at Mass General Brigham (搜索) Cancer Institute and the Peggy S. Blitz Endowed Chair in Hematology/Oncology.
Mechanism and Clinical Impact
Romiplostim works by boosting the bone marrow's ability to withstand the assault of chemotherapy, allowing recipients to continue producing platelets needed to prevent bleeding. Currently, oncologists are forced to dose reduce and delay chemotherapy repeatedly to prevent life-threatening bleeding in patients with chemotherapy-induced thrombocytopenia.
"We know from other studies that this chemotherapy intensity reduction results in worsened outcomes of cancer treatment, including reduced overall survival and lower chance of cancer cure," Al-Samkari explained. "Therefore, we hope that romiplostim's ability to allow administration of full-dose chemotherapy delivered on time will translate into longer survival for patients."
Phase 3 RECITE Trial Results
The phase 3 RECITE trial included 165 patients with advanced colorectal cancer, gastroesophageal cancer, or pancreatic cancer. The study randomized 109 patients to the romiplostim group and 56 to the placebo group.
Patients taking romiplostim demonstrated dramatically improved outcomes, with more than 10-fold lower odds of requiring chemotherapy dose reduction due to chemotherapy-induced thrombocytopenia. No chemotherapy dose modifications were necessary in 84% of patients in the romiplostim group compared to only 36% in the placebo group.
Safety Profile
The safety analysis revealed that adverse events of grade 3 or higher occurred in 37% of patients who received romiplostim compared to 22% of those who received placebo. However, these events primarily reflected the adverse effects of the multiagent chemotherapy patients were receiving, along with the fact that patients on romiplostim were able to receive higher doses of chemotherapy.
Adverse events specifically related to romiplostim or placebo occurred in 12% of patients taking romiplostim and 7% of those taking placebo. The most frequent drug-related adverse events were nausea (2% in each group) and headache (2% in the romiplostim group). Importantly, none of these adverse events were serious or led to death or discontinuation of romiplostim, placebo, or chemotherapy.
Clotting-related adverse events occurred in 2% of patients taking romiplostim and in no patients taking placebo, demonstrating an acceptable safety profile for this mechanism of action.